
Alkermes plc (ALKS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
306.5M
Gross Profit
257.3M
83.95%
Operating Income
13.8M
4.50%
Net Income
22.5M
7.33%
EPS (Diluted)
$0.13
Balance Sheet Metrics
Total Assets
2.1B
Total Liabilities
570.4M
Shareholders Equity
1.5B
Debt to Equity
0.38
Cash Flow Metrics
Operating Cash Flow
122.3M
Free Cash Flow
88.7M
Revenue & Profitability Trend
Alkermes plc Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.6B | 1.7B | 1.1B | 1.2B | 1.0B |
Cost of Goods Sold | 245.3M | 253.0M | 218.1M | 197.3M | 178.3M |
Gross Profit | 1.3B | 1.4B | 893.7M | 976.4M | 860.4M |
Gross Margin % | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% |
Operating Expenses | |||||
Research & Development | 245.3M | 270.8M | 272.7M | 290.9M | 394.6M |
Selling, General & Administrative | 645.2M | 689.8M | 590.8M | 549.6M | 538.8M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 890.6M | 960.6M | 863.5M | 840.5M | 933.4M |
Operating Income | 420.6M | 414.1M | -6.1M | 97.7M | -112.4M |
Operating Margin % | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% |
Non-Operating Items | |||||
Interest Income | 42.4M | 30.9M | 7.6M | 2.4M | 7.0M |
Interest Expense | 22.6M | 23.0M | 13.0M | 11.2M | 8.7M |
Other Non-Operating Income | 3.2M | -425.0K | -19.6M | -1.2M | 17.6M |
Pre-tax Income | 443.8M | 421.5M | -31.1M | 87.7M | -96.5M |
Income Tax | 71.6M | -97.6M | 2.0M | 11.3M | 14.3M |
Effective Tax Rate % | 16.1% | -23.2% | 0.0% | 12.9% | 0.0% |
Net Income | 367.1M | 355.8M | -158.3M | -48.2M | -110.9M |
Net Margin % | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% |
Key Metrics | |||||
EBITDA | 494.9M | 519.5M | 81.5M | 179.0M | -10.0M |
EPS (Basic) | $2.22 | $2.14 | $-0.97 | $-0.30 | $-0.70 |
EPS (Diluted) | $2.17 | $2.10 | $-0.97 | $-0.30 | $-0.70 |
Basic Shares Outstanding | 165392000 | 166223000 | 163742000 | 160942000 | 158803000 |
Diluted Shares Outstanding | 165392000 | 166223000 | 163742000 | 160942000 | 158803000 |
Income Statement Trend
Alkermes plc Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 291.1M | 457.5M | 292.5M | 337.5M | 273.0M |
Short-term Investments | 460.5M | 316.0M | 316.0M | 198.8M | 362.1M |
Accounts Receivable | 315.3M | 229.6M | 216.2M | 313.2M | 275.1M |
Inventory | 182.9M | 186.4M | 181.4M | 150.3M | 125.7M |
Other Current Assets | 91.3M | 98.2M | 41.2M | 49.0M | 60.7M |
Total Current Assets | 1.4B | 1.5B | 1.1B | 1.1B | 1.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 84.2M | 91.5M | 97.5M | 115.6M | 131.7M |
Goodwill | 166.9M | 168.0M | 203.7M | 259.8M | 296.9M |
Intangible Assets | 890.0K | 2.0M | 37.7M | 74.0M | 111.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 171.3M | 207.4M | 260.9M | 109.3M | 128.2M |
Total Non-Current Assets | 640.2M | 650.7M | 833.7M | 962.3M | 838.8M |
Total Assets | 2.1B | 2.1B | 2.0B | 2.0B | 1.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 45.6M | 65.6M | 32.8M | 55.7M | 46.0M |
Short-term Debt | 6.2M | 8.7M | 12.9M | 19.2M | 18.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | 4.5M | 5.8M | - | - |
Total Current Liabilities | 465.2M | 520.2M | 497.7M | 471.3M | 438.3M |
Non-Current Liabilities | |||||
Long-term Debt | 69.4M | 363.4M | 366.6M | 397.0M | 391.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 56.0M | 49.9M | 42.4M | 43.6M | 36.5M |
Total Non-Current Liabilities | 125.4M | 413.3M | 422.5M | 440.6M | 444.5M |
Total Liabilities | 590.6M | 933.5M | 920.2M | 911.9M | 882.7M |
Equity | |||||
Common Stock | 1.8M | 1.7M | 1.7M | 1.7M | 1.6M |
Retained Earnings | -976.5M | -1.3B | -1.7B | -1.5B | -1.5B |
Treasury Stock | 419.3M | 189.3M | 160.9M | 142.7M | 126.1M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.5B | 1.2B | 1.0B | 1.1B | 1.1B |
Key Metrics | |||||
Total Debt | 75.5M | 372.2M | 379.4M | 416.2M | 410.2M |
Working Capital | 950.2M | 965.3M | 632.6M | 590.9M | 672.7M |
Balance Sheet Composition
Alkermes plc Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 367.1M | 355.8M | -158.3M | -48.2M | -110.9M |
Depreciation & Amortization | 28.5M | 74.9M | 77.9M | 78.7M | 81.9M |
Stock-Based Compensation | 96.6M | 100.9M | 94.3M | 87.6M | 90.2M |
Working Capital Changes | -109.2M | -13.3M | 3.1M | -48.5M | -41.5M |
Operating Cash Flow | 428.1M | 424.7M | 11.5M | 78.7M | 28.2M |
Investing Activities | |||||
Capital Expenditures | -33.0M | -47.7M | -38.3M | -27.7M | -41.6M |
Acquisitions | 98.0M | 0 | 1.8M | 7.9M | 6.6M |
Investment Purchases | -486.5M | -254.5M | -309.7M | -340.4M | -229.5M |
Investment Sales | 310.3M | 355.5M | 281.6M | 295.0M | 253.0M |
Investing Cash Flow | -111.3M | 53.4M | -63.3M | -57.3M | -7.6M |
Financing Activities | |||||
Share Repurchases | -200.3M | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | 0 | 0 | 23.6M | 0 |
Debt Repayment | -291.8M | -3.0M | -3.0M | -3.2M | -2.8M |
Financing Cash Flow | -521.7M | -306.5M | -21.2M | 3.8M | -10.5M |
Free Cash Flow | 405.6M | 353.3M | -17.2M | 72.7M | 40.6M |
Net Change in Cash | -205.0M | 171.6M | -73.0M | 25.2M | 10.1M |
Cash Flow Trend
Alkermes plc Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.03
Forward P/E
14.45
Price to Book
2.95
Price to Sales
3.19
PEG Ratio
-7.58
Profitability Ratios
Profit Margin
23.15%
Operating Margin
23.80%
Return on Equity
23.94%
Return on Assets
10.49%
Financial Health
Current Ratio
3.23
Debt to Equity
4.47
Beta
0.42
Per Share Data
EPS (TTM)
$2.07
Book Value per Share
$9.84
Revenue per Share
$9.21
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alks | 4.8B | 14.03 | 2.95 | 23.94% | 23.15% | 4.47 |
Zoetis | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 43.6B | 21.44 | 5.44 | 9.38% | 13.81% | 53.41 |
Elanco Animal Health | 8.9B | 20.41 | 1.32 | 6.83% | 9.68% | 62.13 |
Regencell Bioscience | 6.6B | - | 960.00 | -47.77% | 0.00% | 0.01 |
Prestige Consumer | 3.8B | 17.92 | 2.07 | 12.30% | 18.86% | 56.91 |
Financial data is updated regularly. All figures are in the company's reporting currency.